News

In an effort to help ensure patient safety and alleviate strain on healthcare resources during the COVID-19 pandemic, Astellas is implementing changes to our clinical trial operations. In countries with rapid growth of new COVID-19 cases, Astellas is suspending start-up activities involving study sites for new interventional clinical studies. We are also suspending enrollment of new patients in...

- Collaboration to Utilize CytomX’s Novel Probody® Technology Platform for CD3 Bispecific Targets - - CytomX to Receive $80 Million Upfront Payment and Ability to Exercise Option for U.S. Co-Commercialization Rights - SOUTH SAN FRANCISCO, CA and Tokyo, March 23, 2020 - CytomX Therapeutics, Inc. (NASDAQ: CTMX, President, Chief Executive Officer and Chairman: Sean McCarthy, D. Phil. “CytomX”) and...

TOKYO , March 18, 2020 - Gifu University (President: Hisataka Moriwaki M.D., Ph.D.) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the parties have established, inside Gifu University Graduate School of Medicine, a joint research course entitled, “Phage Biologics Research Course” (Lead professor: Hiroki Nagai, Ph.D., Professor of...